Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
that is what we are seeing!!! This ''bounce'' will ''draw in the mugs'' who think the falls are over. This will fall further, but will recover strongly.
Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities.
"We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said.
"With the performance wanting we would hope all options are now on the table to maximise shareholder value."
https://www.ft.com/content/07bc74d8-d04d-11e8-a9f2-7574db66bcd5
Best of luck Mr LMAO. I’m only a “bear” if I think something is overpriced or overhyped. Or if it is clearly rudderless...unless of course you think this was a planned retirement :)
In the long line of IPOs by private equity this is another sorry tale in the same recent mould as the AA, Saga and Spire.
Convatec operate in a very difficult & competitive sector with little sales price inflation and a continuous need to push unit costs lower. CEO removed sharpish and a NED rushed in sounds like an Aviva type of move!!! Plus a chair and a deputy chair who wouldn’t know a colostomy from a colonoscopy doesn’t exactly provide confidence.
Finance Director did, I did, then I bought more after his transaction announcement
Wish I'd bought in today now. I'm sure there'll be an opportunity tomorrow.
Broker Reiterations
Director Buys
Interim CEO from big Pharma
All positives so should be upward from here
The Finance Director hopefully knows the Company is in excellent shape, bar this temporary issue, and they will soon be back on track. Often these dramas do not present a great opportunity to invest but this is different
Yep, was hoping for something like that. Hopefully it will stop the free-fall.
Director Buys shows confidence - a good move
I concur and have also gone Long
I've bought some as I too think the drop is way over done.
Fingers crossed that is the case...
Whats the 3 day rule ?
Sold ages ago. Tempting at these levels to buy in again.
under 160p today!!
And now back in at 205p
Recovery back and beyond 230p , I hope. Piled into this in the 190s this time around Amazing to see sub 200s again!
Seems to be climbing on no significant news. What are you views on the trading update? Are we exoecting it to be a positive or nehative for the shate price?
Paul Moraviec, CEO of ConvaTec, said: "The addition of J&R Medical to our Home Distribution Group will strengthen our presence in a substantial and important US market. The acquisition also reinforces ConvaTec's position as a leading distributor of urinary catheters in the US."
ConvaTec Group Plc ("ConvaTec") a leading global medical products and technologies company focused on therapies for the management of chronic conditions, today announces the acquisition of J&R Medical LLC ("J&R Medical"), a Texas-based independent distributor of catheter-related supplies. For the year ended 31 December 2017 J&R Medical delivered revenues of approximately $9.0 million.
Buy Convetec for recovery,says Share Centre Strong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a �long way� from their highs and remain a buying opportunity, believes The Share Centre. Analyst Helal Miah retained his �buy� recommendation for �investors seeking a recovery potential and willing to accept a higher level of risk� following last week�s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday. �Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,� said Miah. �While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.� He added that the underlying market for Convatec is �defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions�.
Exactly what was needed , good point for me was the divvy and the buying of the USA distribution business . Suspect normal mm games but see no reason for this not to go up from here over the next month or so . Main shareprice point going forward is if this re-enters footse 100 trackers have to buy back in , these will be solid holders as long as it stays in the index . Gla
ConvaTec Group Plc Annual Results 2017 https://www.investegate.co.uk/convatec-group-plc--ctec-/rns/final-results/201802150700059401E/ "Supply constraints previously reported in Advanced Wound Care and Ostomy Care now resolved, anticipate ongoing impact in H1 2018 from Ostomy backorder fulfilment, and lost orders;...."
Anyone read RNS? Sounds all good to me. Supply probs fixed. Beat revised organic growth target .